Geron Co. (NASDAQ:GERN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Geron Co. (NASDAQ:GERN) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.75.

A number of equities research analysts have weighed in on the company. Barclays reiterated an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Stifel Nicolaus dropped their target price on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Scotiabank dropped their price objective on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research note on Wednesday, March 12th.

Institutional Trading of Geron

Institutional investors and hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Geron in the fourth quarter valued at about $28,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Geron during the 4th quarter valued at $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron during the fourth quarter worth about $45,000. 111 Capital purchased a new stake in shares of Geron during the 4th quarter worth approximately $52,000. Finally, Fifth Lane Capital LP purchased a new stake in shares of Geron during the 4th quarter worth approximately $53,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Stock Down 0.6 %

Shares of NASDAQ GERN opened at $1.73 on Wednesday. The company has a market capitalization of $1.10 billion, a P/E ratio of -5.41 and a beta of 0.53. Geron has a 52-week low of $1.46 and a 52-week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The company’s 50 day moving average price is $2.51 and its 200-day moving average price is $3.52.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Equities analysts forecast that Geron will post -0.25 earnings per share for the current year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.